TABLE 2.
Sample type and parametera | Valueb for:
|
P value | |
---|---|---|---|
Diabetic subjects (n = 6) | Healthy subjects (n = 6) | ||
Plasmac | |||
Cmax (μg/ml) | 67.8 ± 11.1 | 62.4 ± 9.8 | 0.40 |
AUC0-∞ (μg·h/ml) | 496.7 ± 123.1 | 450.5 ± 43.0 | 0.41 |
t1/2 (h) | 9.3 ± 1.6 | 8.1 ± 0.6 | 0.13 |
CL (ml/h/kg) | 8.4 ± 1.7 | 9.0 ± 0.9 | 0.50 |
Vss (ml/kg) | 101.7 ± 18.2 | 97.6 ± 5.4 | 0.94 |
Tissue | |||
Cmax (μg/ml) | 4.3 ± 3.3 | 3.8 ± 1.4 | 0.73 |
Tmax (h) | 1.5 ± 0.8 | 1.3 ± 0.8 | 0.70 |
AUC0-∞ (μg·h/ml) | 45.1 ± 40.6 | 33.5 ± 8.1 | 0.82 |
t1/2 (h) | 12.4 ± 4.7 | 8.8 ± 1.8 | 0.24 |
Cmin (μg/ml) | 0.59 ± 0.58 | 0.39 ± 0.13 | 0.94 |
Penetration ratio (AUCtissue/fAUCplasma) | 0.93 ± 0.61 | 0.74 ± 0.09 | 0.46 |
CL, clearance; Vss, steady-state volume of distribution; Tmax, time to reach peak concentration.
Data are reported as means ± standard deviations.
Plasma parameters are based on total drug concentrations.